Brian T. Chamberlain

Author

Also Known As

B.T. Chamberlain, Brian Chamberlain, Brian T Chamberlain, Brian T. Chamberlain, Brian T. Chamberlain, Chamberlain, Brian T.

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

California NanoSystems Institute University of California, Los Angeles Cubist Pharmaceuticals (United States)University of Southern California Howard Hughes Medical Institute

About

Brian T. Chamberlain is an author at California NanoSystems Institute specializing in medicine, natural sciences, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	773
2	Natural Sciences	8	8	287
3	Engineering	3	3	78
4	Social Sciences	2	2	241
5	Behavioral Sciences	2	2	241

Brian T. Chamberlain

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
LXRs Regulate ER Stress and Inflammation through Dynamic Modulation of Membrane Phospholipid Composition Xin Rong, Carolyn J. Albert, Cynthia Hong, Cell Metabolism InflammationMolecular PhysiologySignal TransductionPhysiologyImmunology	2013	309
An Essential Requirement for the SCAP/SREBP Signaling Axis to Protect Cancer Cells from Lipotoxicity Kevin Jon Williams, Joseph P. Argus, Yue Zhu, Cancer Research	2013	189
The effect of raising or lowering tryptophan levels on aggression in vervet monkeys Brian T. Chamberlain, Frank R. Ervin, Robert O. Pihl, Pharmacology Biochemistry and Behavior Behavioral SciencesBehavioral NeuroscienceSocial BehaviorVervet MonkeysTryptophan Levels	1987	123
Acute effect of altered tryptophan levels and alcohol on aggression in normal human males R. O. Pihl, Simon N. Young, Philip W. Harden, Psychopharmacology Behavioral SciencesBehavioral NeuroscienceAddictionAlcohol DependencePsychopharmacology	1995	118
Selective inhibitor of endosomal trafficking pathways exploited by multiple toxins and viruses Eugene J. Gillespie, Chi-Lee C. Ho, Kavitha Balaji, Proceedings of the National Academy of Sciences Bioorganic ChemistryToxinologyMolecular BiologyAntimicrobial ChemotherapyChemical Biology	2013	91
The LXR–Idol Axis Differentially Regulates Plasma LDL Levels in Primates and Mice Cynthia Hong, Stephanie Marshall, Allison L. McDaniel, Cell Metabolism Knockout MouseMolecular RegulationImmunologyVascular BiologyMedicine	2014	86
A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury Maria Kost‐Alimova, Eriene-Heidi Sidhom, Abhigyan Satyam, Cell Reports Medicine	2020	70
Discovery of Pyrazolopyridones as a Novel Class of Gyrase B Inhibitors Using Structure Guided Design Jason B. Cross, Jing Zhang, Qingyi Yang, ACS Medicinal Chemistry Letters Combinatorial ChemistryDrug TargetBioorganic ChemistryMolecular BiologyAntimicrobial Chemotherapy	2016	46
Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B Inhibitors Jing Zhang, Qingyi Yang, Jan Antoinette C. Romero, ACS Medicinal Chemistry Letters Indazole DerivativesMedicinal ChemistryBiochemistryMedicineAntibacterial Activity	2015	32
Stereospecific Formation of a Ternary Complex of (<i>S</i>)‐α,β‐Fluoromethylene‐dATP with DNA Pol β Brian T. Chamberlain, V.K. Batra, William A. Beard, ChemBioChem	2012	31

Page 1